Living with advanced lung cancer is a heavy burden, and finding the most effective treatment path is vital for patients and their families. A new trial is looking at a specific type of lung cancer called non-small-cell lung cancer that cannot be removed by surgery.
Researchers are testing a new sequence of care. Instead of starting with radiation and chemotherapy, they want to see if adding an immunotherapy drug called durvalumab at the very beginning helps. This initial step, called induction therapy, is designed to see if it improves the chances of survival and slows the growth of the cancer.
Because this is a trial protocol, the study is currently in the design and enrollment phase. This means the researchers have not collected or shared any results yet. The study will involve 212 patients to see if this specific combination of drugs and radiation works better than the current standard of care.
